Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Pulse Biosciences ( (PLSE) ).
On February 5, 2026, Pulse Biosciences reported 6- and 12‑month results from its first‑in‑human feasibility study of the nPulse Cardiac Catheter System for treating atrial fibrillation, with data presented at the 31st Annual AF Symposium in Boston. In a 150‑patient cohort treated at European centers, the endocardial catheter ablation device, designed to deliver circumferential ablation using proprietary nanosecond PFA energy, achieved 100% procedural success among evaluable patients at six months (75/75) and 96% at 12 months (45/47), with an average of 16.1 applications per procedure, relatively short procedure and fluoroscopy times, and a low 1.3% rate of serious adverse events related to the primary safety endpoint. Company and clinical leaders characterized the results as demonstrating an efficient workflow, durable pulmonary vein isolation, and a favorable safety profile versus typical atrial fibrillation recurrence expectations, positioning the nPulse system as a potentially first‑in‑class and highly differentiated catheter ablation platform as Pulse Biosciences advances its clinical program.
The most recent analyst rating on (PLSE) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Pulse Biosciences stock, see the PLSE Stock Forecast page.
Spark’s Take on PLSE Stock
According to Spark, TipRanks’ AI Analyst, PLSE is a Neutral.
The score is held down primarily by very weak financial performance (minimal revenue, negative gross profit, large losses, and persistent cash burn), with a downtrend-leaning technical setup adding pressure. Offsetting this somewhat are a comparatively low-leverage balance sheet and a more constructive earnings-call backdrop driven by trial/regulatory progress and early commercial traction.
To see Spark’s full report on PLSE stock, click here.
More about Pulse Biosciences
Pulse Biosciences is a bioelectric medicine company focused on its proprietary nPulse nanosecond pulsed field ablation (nsPFA) technology, which delivers ultrashort electrical pulses to non‑thermally clear targeted cells while sparing surrounding noncellular tissue. The company is developing this platform primarily for the treatment of atrial fibrillation via catheter-based ablation and is also exploring select additional markets such as surgical soft tissue ablation where its technology could materially improve procedural efficiency and patient outcomes.
Average Trading Volume: 184,448
Technical Sentiment Signal: Buy
Current Market Cap: $1.02B
See more data about PLSE stock on TipRanks’ Stock Analysis page.